Consensus Eli Lilly and Company Deutsche Boerse AG

Equities

LLY

US5324571083

Real-time Estimate Tradegate Other stock markets 01:12:11 16/05/2024 am IST			5-day change	1st Jan Change
720 ^EUR	+2.10%		-0.24%	+36.71%

04:49pm	UK weight-loss drug price rivalry intensifies with Pharmacy2U mark-down	RE
02:43pm	Eli Lilly Ethics/Compliance Chief Alonzo Weems to Retire	DJ

Evolution of the average Target Price on Eli Lilly and Company

Price target over the last 5 years

History of analyst recommendation changes

9.oERp2rEAyJHGnGdX9AM14JN8v8yv7z37_zSL9kKAfzE.7zw2mfBnsaD12hdipzBRtec5iPTZjVjCuhnxnAe0SlzHc1_39Wy_o4vxPg~dd16373fce67d811c61fae667432cfff

Analyst Recommendations on Eli Lilly and Company

Argus Adjusts Price Target on Eli Lilly to $840 From $770	14/05	MT
Redburn Atlantic Adjusts Eli Lilly Price Target to $600 From $540	14/05	MT
China Merchants Initiates Eli Lilly at Buy Rating With $852 Price Target	08/05	MT
JPMorgan Adjusts Price Target on Eli Lilly to $900 From $850	01/05	MT
Wolfe Research Adjusts Price Target on Eli Lilly to $909 From $813	01/05	MT
Barclays Adjusts Price Target on Eli Lilly and Company to $913 From $810	01/05	MT
BMO Capital Adjusts Eli Lilly Price Target to $1,001 From $900	01/05	MT
Leerink Partners Adjusts Price Target on Eli Lilly to $901 From $821	01/05	MT
Deutsche Bank Adjusts Price Target on Eli Lilly to $725 From $695	01/05	MT
Truist Raises Price Target on Eli Lilly to $892 From $850, Keeps Buy Rating	01/05	MT
Goldman Sachs Adjusts Price Target on Eli Lilly to $740 From $723	01/05	MT
Wells Fargo Adjusts Eli Lilly Price Target to $875 From $825	01/05	MT
Morgan Stanley Raises Price Target on Eli Lilly to $1,023 From $950 Amid 2024 Guidance Boost, Keeps Overweight Rating	01/05	MT
Jefferies Adjusts Eli Lilly and Co.'s Price Target to $915 From $895, Keeps Buy Rating	30/04	MT
Jefferies Raises Eli Lilly's Price Target to $895 From $885, Buy Rating Kept	17/04	MT
BMO Raises Price Target on Eli Lilly to $900 From $865	12/04	MT
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech	12/04	MT
Goldman Sachs Raises Price Target on Eli Lilly to $723 From $650, Maintains Neutral Rating	11/04	MT
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech	11/04	MT
ANALYST RECOMMENDATIONS : Estee Lauder, Humana, Eli Lilly, National Grid, Brown-Forman...	02/04
Top Midday Stories: Bankman-Fried Gets 25-Year Prison Sentence; Home Depot Acquiring SRS Distribution; Walgreens Lowers FY 2024 Outlook; Analyst Says Short MicroStrategy; Canadian School Boards Sue Social Media Platforms; Eli Lilly Weight-Loss Drug Facing Shortage	28/03	MT
JPMorgan Raises Eli Lilly's Price Target to $850 From $775, Maintains Overweight Rating	15/03	MT
UBS Adjusts Eli Lilly Price Target to $910 From $810, Maintains Buy Rating	04/03	MT
ANALYST RECOMMENDATIONS : Doordash, Merck, Eli Lilly, Walt Disney, Pearson...	04/03
Eli Lilly: stock rises, BofA targets $1,000	01/03	CF

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

764 USD

Average target price

850.4 USD

Spread / Average Target

+11.31%

High Price Target

1,023 USD

Spread / Highest target

+33.90%

Low Price Target

540 USD

Spread / Lowest Target

-29.32%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Eli Lilly and Company

Argus
Redburn Atlantic
China International Capital
JPMorgan Chase
Wolfe Research
Barclays
BMO Capital
Leerink Partners
Deutsche Bank Securities
Truist Securities
Goldman Sachs
Wells Fargo Securities
Morgan Stanley
Jefferies & Co.
UBS
BofA Securities
DZ Bank
JEFFERIES	Akash Tewari
Cantor Fitzgerald
Morningstar
Guggenheim
Daiwa Securities
Berenberg Bank
Citigroup
Credit Suisse
HSBC
TD Cowen
SVB Securities LLC
Cowen
Mizuho Securities

Ratings for Eli Lilly and Company

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar